Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study

PURPOSE: The clinical activity observed in a phase I dose-escalation study of concurrent therapy with nivolumab (NIVO) and ipilimumab (IPI) in patients with previously treated or untreated advanced melanoma led to subsequent clinical development, including randomized trials. Here, we report long-ter...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Callahan, Margaret K., Kluger, Harriet, Postow, Michael A., Segal, Neil H., Lesokhin, Alexander, Atkins, Michael B., Kirkwood, John M., Krishnan, Suba, Bhore, Rafia, Horak, Christine, Wolchok, Jedd D., Sznol, Mario
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2018
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5946731/
https://ncbi.nlm.nih.gov/pubmed/29040030
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.72.2850
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados